Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Blood

Volumn 107, Issue 7, 2006, Pages 2912-2919

  Moser, Elizabeth C ^a   Noordijk, Evert M ^a   Van Leeuwen, Flora E ^a   Le Cessie, Saskia ^a   Baars, Joke W ^a   Thomas, José ^a   Carde, Patrice ^a   Meerwaldt, Jacobus H ^a   Van Glabbeke, Martine ^a   Kluin Nelemans, Hanneke C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGISTER; SALVAGE THERAPY; STROKE;

EID: 33645526451     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3392     Document Type: Article

References (56)

1. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31.
2. Bhatia S, Robinson LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745-751.
3. Haddy TB, Adde MA, McCalla J, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol. 1998;6:2070-2079.
4. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222-1228.
5. Aviles A, Diaz-Maqueo JC, Garcia EL, Talavera A, Huerta-Guzman J, Neri N. Late lethal events in patients with diffuse large B cell lymphoma, a review of 714 patients treated in a single centre. Leuk Lymphoma. 2001;42:631-637.
6. Moser EC, Noordijk EM, Carde P, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005;6:122-130.
7. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949-1955.
8. Aviles A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005;46:1023-1028.
9. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol. 2003;42:589-604.
10. King V, Constine LS, Clark D, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1996;36:881-889.
11. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1998;46:51-62.
12. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-2837.
13. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
14. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
15. Aviles A, Delgado S, Fernandez R, Talavera A, Neri N, Huerta-Guzman J. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002;68:144-149.
16. Wilder RB, Rodriguez MA, Tucker SL, et al. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys. 2001;50:743-749.
17. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
18. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
19. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-3131.
20. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30:181-191.
21. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
22. Cowie MR, Wood DA, Coats AJ, et al. Incidence and etiology of heart failure. A population-based study. Eur Heart J. 1999;20:421-428.
23. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;357:995-1001.
24. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675-687.
25. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000;355:688-700.
26. Empana JP, Ducimetiere P, Arveiler D, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;21:1903-1911.
27. Paul I, Bilge A, Bolly F, Boland J, Reginster JY. Pilot study for the registration of acute myocardial infarction in the Liege area (Belgium). Rev Epidemiol Sante Publique. 2001;5:423-429.
28. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
29. van der Pal-de Bruin KM, Verkleij H, Jansen J, Bartelds A, Kromhout D. The incidence of suspected myocardial infarction in Dutch general practice in the period 1978-1994. Eur Heart J. 1998;19:429-434.
30. Lisdonk van de EH, Bosch van den WJHM, Huygen FJA, Lagro-Jansen ALM. Ziekten in de huisartspraktijk (3e druk). Maarssen, Germany: Elsevier/Bunge; 1999.
31. Gijssen R, Poos MJJM. Achtergronden en details bij cijfers uit huisartsenregistraties. Gezondheid en ziekte\ziekte en aandoeningen\ hartvaatstelsel\coronaire hartziekten. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven, RIVM; 2003. Available at: http://www.rivm.nl/vtv/object_class/kom_hartvaat.html. Accessed on December 15, 2005.
32. Somers R, Carde P, Thomas J, et al. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. Ann Oncol. 1994;5:S85-S89.
33. Meerwaldt JH, Carde P, Somers R, et al. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/ prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol. 1997;8:S67-S70.
34. Carde P, Meerwaldt JH, van Glabbeke M, et al. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group. Ann Oncol. 1992;2:431-435.
35. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001;93:22-30.
36. Breslow NE, Day NE. Statistical methods in cancer research. Volume II: the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1-406.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
38. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
39. Cox DR. Regression models and life-tables. J Royal Stat Soc Ser B. 1972;334:187-202.
40. Koek HI, Van Leest LATM, Verschuren WMM, et al. Cardiovascular Disease in the Netherlands 2004, Details on Life-style and Risk Factors, Disease and Mortality. The Hague, The Netherlands: Dutch Cancer Foundation; 2004.
41. Bots ML, Looman SJ, Koudstaal PJ, Hofman A, Hoes A, Grobbee DE. Prevalence of stroke in the general population. The Rotterdam Study. Stroke. 1996;9:1499-1501.
42. Fox KF, Cowie MR,Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22:228-236.
43. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
44. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;2:277-281.
45. Swain M, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97:2869-2879.
46. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-1677.
47. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:S72-S85.
48. Brosius FC, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519-530.
49. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;8:766-773.
50. Zinzani PL, Gherlinzoni F, Piovaccari G, et al. Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica. 1996;81:132-137.
51. Constine LS, Schwartz RG, Savage DE, King V, Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1997;39:897-906.
52. Dorresteijn LD, Kappelle AC, Boogerd W, et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol. 2002;20:282-288.
53. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864-1871.
54. Adams MJ, Lipsitz SR, Colan SD. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139-3148.
55. Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma [abstract]. Ann Oncol. 2005;16:118. Abstract no. 276.
56. Moser EC, Noordijk EM, van Leeuwen FE, et al. Relative risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymphoma [abstract]. Blood. 2005;106:794a. Abstract no. 2831.